12. CONCLUSÕES:
1) A freqüência de esteato-hepatite não alcoólica e esteatose hepática foi elevada na população em estudo, observando-se inclusive 5% de cirrose instalada.
2) Houve correlação entre glicemia, triglicérides, ferro e ferritina com anormalidades enzimáticas hepáticas, na análise univariada.
3) Na análise multivariada incluindo classificação histológica hepática apenas a albumina revelou-se variável determinante para a separação diagnóstica; no entanto todos os valores desta estavam na faixa da normalidade, e as oscilações eram modestas, o que debilita o valor preditivo da determinação.
4) Tornou-se evidente que a avaliação histológica deve ser o critério dominante para diagnóstico e acompanhamento desta população, dada a ausência de correlações clínicas confiáveis para os testes bioquímicos gerais, e à correlação com limitações inerente à dosagem de albumina sérica.
Referências bibliográficas
REFERÊNCIAS BIBLIOGRÁFICAS
1. Jebb SA. Obesity: from molecules to man. Proc Nutr Soc. 1999;58:1-14.
2. Pereira LO, Francischi RP, Klopfer M, Sawada LA, Santos R, Vieira P, et al. Obesidade e suas implicações – Ação da Atividade Física e Controle Nutricional. Rev Bras Nutr Clin 1999;14:9-17.
3. WHO - World Health Organization. Obesity – preventing and managing the global epidemic. Geneva: Report of a WHO Consultation on Obesity, 1998.
4. Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998;56:106-14.
5. O'dea K. Westernization and non-insulin-dependent diabetes in Australian Aborigines. Ethn Dis 1991;1:171-87.
6. Defronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
7. Mcnamara DJ, Howell WH. Epidemiologic data linking diet to hyperlipidemia and arterioscleroses. Semin Liver Dis 1992;12:347-55.
Referências bibliográficas
8. Stunkard AJ, Wadden TA. Psychological aspects of human obesity. In: Björntorp P, Brodoff BN, editors. Obesity. Philadelphia: J.B. Lippincott Company, 1992:352-60.
9. Björntorp P, Brodoff BN. Obesity. Philadelphia:J.B. Lippincott Company, 1992.
10. Després JP, Lamarche B. Low intensity endurance exercise training, plasma lipoporotein and the risk of coronary heart disease. J Intern Med 1994;236:7-22.
11. Youssef WI, McCullough AJ. Diabeteses mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002;13:17–30
12. Angelico F. Del Ben M. Conti R. Francioso S. Feole K. Fiorello S. Cavallo MG. Zalunardo B. Lirussi F. Alessandri C. Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. Journal of Clinical Endocrinology & Metabolism.2005 Mar; 90(3):1578-82.
13. Zhang WM, Kuchár S, Mozes S. Body fat and RNA content of the VMH cells in rats neonatally treated with monosodium glutamate. Brain Res Bull 1994;35:383-5.
14. Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science 1998;280:1371-4.
Referências bibliográficas
15. WHO - World Health Organization. Diet, nutrition and the prevention of chronic diseases. Geneva: Technical Report Series, 1990:797.
16. WHO - World Health Organization. Physical Status: the use and interpretation of anthropometry. Geneva: Technical Report Series, 1995:854.
17. Rolls BJ, Shide DJ. The influence of dietary fat on food intake and body weight. Nutr Rev 1992;5:283-90.
18. Schulz LO, Schoeller DA. A compilation of total daily energy expenditures and body weights in healthy adults. Am J Clin Nutr 1994;60:676-81.
19. Haapanen N, Miilunpalo S, Oja P, Vuori I. Association between leisure time physical activity and 10-year body mass change among working-aged men and women. Int J Obes Relat Metab Disord 1997;21:288-96.
20. Grundy SM. Multifactorial causation of obesity: implications for prevention. Am J Clin Nutr 1998;67:563-72.
21. Melby CL, Commerford SR, Hill JO. Exercise, macronutrient balance, and weight control. In: Lamb DR, Murray R, editors. Perspectives in Exercise Science and Sports Medicine vol. 11: Exercise, Nutrition, and Weight Control. Carmel: Cooper Publishing Group, 1998:1-60.
22. Hill JO, Melanson EL, Wyatt HT. Dietary fat intake and regulation of energy balance: implications for obesity. J. Nutr 2000;120:284-8.
Referências bibliográficas
23. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Genebra: WHO, 2002.
24. Kopelman PG. Obesity the the medical problem. Nature 2000;404:635– 643;3. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among us children, adolescents, and adults, 1999–2002. JAMA 2004;291:2847–2850.
25. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11.
26. US National Institute of Health. Clinical Guidelines on the Identification, Evaluations and Treatment of overweight and obesity in adults. Am J Clin Nutr,1998; 138, 899-917.
27. Monteiro CA, Mondini L, Souza ALM, Popkin BM. Da desnutrição para a obesidade: a transição nutricional no Brasil. In: Monteiro CA, editor. Velhos e novos males da saúde no Brasil – a evolução do país e de suas doenças. São Paulo: Hcitec-NUPENS/USP, 1995:247-55.
28. Monteiro CA, Mondini L, Souza ALM, Popkin BM. The nutrition transition in Brazil. Eur J Clin Nutr 1995;49:105-13.
Referências bibliográficas
29. Francischi RP, Pereira LO, Freitas CS, Klopfer M, Santos RC, Viera P, et al. Obesidade: atualização sobre sua etiologia, morbidade e tratamento. Rev Nutr 2000;13:17-28.
30. Francischi RP, Pereira LO, Lancha Jr AH. Exercício, comportamento alimentar e obesidade: revisão dos efeitos sobre a composição corporal e parâmetros metabólicos. Rev Paul Educ Fís 2001;15:117-40.
31. Wanless GO, Lentz JS. Fatty Liver Hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–1110
32. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100
33. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117–1123
34. Marceau P, Biron S, Hould FS, et al. Liver Pathology And The Metabolic Syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513–1517.
35. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M: Prospective Evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol, 1999; 94(10):3010–3014.
Referências bibliográficas
36. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in at general population of Okinawa, Japan. Jpn J Med,1988; 27(2):142–149.
37. Luyckx FH, Desaive C, Thiry At, et al.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord, 1998; 22(3):222–226.
38. Silverman JF, O'Brien KF, Long S, et al.: Liver Pathology In Morbidly Obese Patients With And Without diabeteses. Am J Gastroenterol,1990; 85(10):1349– 1355.
39. Russian MW, Jacobson IM: Nonalcoholic fatty liver disease. Hosp Phy,2002; 67:36–41.
40. Matteoni AC, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: at spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419.
41. Brunt, EM. Nonalcoholic Steatohepatitis. Semin Liver Dis, Volume 24(1).2004.3–20.
42. Adler, M.; and Schaffner, F. Fatty liver hepatitis and cirrhosis in obese patients. Am. J. Med.1979; 67:811.
Referências bibliográficas
43. Diehl, A.M.; Goodman, Z., and Ishak, K. G. Alcohol like liver disease in nonalcoholics. A clinical and histopathological comparission with alcohol- induced liver injury. Gastroenterology 1988;95:1056.
44. Ludwig, J; Viggiano, TR; McGill, DB; Oh, BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-438.
45. Ludwig, J; McGill, DB; Lindor, KD. Metabolic liver diseases. Rewiew: Nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 1997; 12: 398-403.
46. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202– 1219.
47. Dixon JB, O'Brien PE, Bhatal PS. A wider view on diagnostic criteria of nonalcoholic steatohepatitis. Gastroenterology 2002;122:841–842.
48. Deitel, M. Overview of operations for morbid obesity. World. J. Surg. 1998; 2: 913-918.
49. Batman, P A, Scheuer, P J. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 1985;9:237-243.
50. Lee, R G. Nonalcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989;594-599.
Referências bibliográficas
51. Torosis, J D, Barwik, K W, Miller, J D, et al. Nonalcoholic Laennec’s : Clinical characteristics and long term follow up. Hepatology 1985;237-241.
52. Powell, E E, Searle, J, Mortimer R. Steatohepatitis associated with limb lipodistrophy. Gastroenterology 1989;97:10242-1024.
53. Seki, K, Minami T, Nishikawam, et al. Nonalcoholic steatohepatitis induced by massive doses of estrogens. Gastroenterology 1994;107:1103-1106.
54. Fouin-Fortenet H, LeQuernec, L, Erlinger, S, et al. Hepatic alteration during total parenteral nutrition in patients with inflammatory bowel disease: A possible consequense of lithocholate toxicity. Gastroenterology 1982;82:932-938.
55. Youssef WI, McCullough. Steatohepatitis in obese individuals. AJ.Best Prac Clin Gastroenterol 2002 Oct; 16(5):733-47.
56. Allard, JD Toronto General Hospital. Other disease associations with non- alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2002 Oct:16(5):783-95.
57. Afonso, FCS; Radominnski,RB; Suplicy, HL et al. Anormalidades hepáticas em pacientes obesos mórbidos submetidos à cirurgia bariátrica: correlações clínica, ecográfica, anatopatológica e laboratorial . GED 2001; 20(Supl): S84 – PO-217.
Referências bibliográficas
58. Bacon BR, Farahvash MJ, JanneyY CG et al. Nonalcoholic sateatohepatitis: an explaned clinical entity. Gastroenterol Jpn, 1994;107:1103-1109.
59. Day CP, James OF: Steatohepatitis: at tale of two “hits”? Gastroenterology,1998; 114(4):842–845.
60. Shenkin A. Trace elements and inflammatory response. Implications for nutritional support. Nutrition 1995; 11(Suppl): 100-106.
61. Festa, A; Dágostino RB, Howard, G; Mykkanen, L; Tracy RP; Haffner,SM. Chronic subclinical inflammation as part of the insulin resistence syndrome. The Insulin Resistence Atherosclerosis Study (IRAS). Circulation 2000; 201: 42-47.
62. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003 Feb;5(1):18-25
63. Comert B, Mas MR, Erdem H, Dinc A, Saglamkaya U, Cigerim M, Kuzhan O, Unal T, Kocabalkan F. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 2001 May;33(4):353-8
64. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001 Oct;34(4 Pt 1):738-44
Referências bibliográficas
65. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57–69
66. Day CP, Saksena S. Nonalcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17:S377–S384
67. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663–678
68. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003;134:18–27
69. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000 May;4(2):409-29, vi-vii
70. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998 Feb;114(2):311-8
71. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002 Jul;36(1):142-9 Erratum in: Hepatology 2002 Nov;36(5):1307
Referências bibliográficas
72. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001 Aug;96(8):2448-55
73. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999 Nov;117(5):1155-63
74. Day CP, James OF: Steatohepatitis: at tale of two “hits”? Gastroenterology 1998; 114(4):842–845.
75. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: implications be the pathogenesis of steatohepatitis. Proc Natl Acad Sci PLAY ON 1997; 94(6):2557–2562.
76. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The Expression of growth necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95(5):2111–2119.
77. Leclercq GO, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A the microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105(8):1067–1075.
Referências bibliográficas
78. Weltman MD, Farrel GC, Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998; 27:128-133.
79. Pessayre D, Leteron P, Fromenty B et al. Acute and chronich hepatic steatosis lead to in vivo lipid peroxidation in mice. J. Hepatol, 1996; 24:200-208
80. Pessayre D, Fromenty B, Berson A. Microvesilcular steatosis ando seteatohepatitis: role of mitochondrial dysfunction ando lipid peroxidation. J. Hepatol, 1997; 26:13-22
81. Lombardi B. Considerations on the pathogenesis of fatty liver. Lab. Invest, 1996; 15:1-20.
82. Uygun At, Kadayifci At, Yesilova Z, et al.: Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95(12):3584–3589.
83. Chitturi S, Farrell G, Frost L, et al.: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: at manifestation of lipotoxicity? Hepatology 2002; 36(2):403–409.
84. Diehl AM, Yang SQ, Lin HZ et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci, 1997;94:2557-2562.
Referências bibliográficas
85. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16):1221–1231.
86. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol, 1989;20:594-598.
87. Powell EE, Cooksley WG, Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 1990;11:74-80.
88. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The artless history of nonalcoholic steatohepatitis: at follow-up study forty-two patients of be up to 21 years. Hepatology 1990; 11(1):74–80.
89. Angulo P, Keach JC, Batts KP, Lindor KD: Independent Predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6):1356–1362.
90. Sonsuz At, Basaranoglu M, Ozbay G: Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95(5):1370–1371.
91. Sorbi D, Boynton J, Lindor KD. The ratio aspartato aminostransferase to alanine aminostransferase: potential value in differentiating nonalcoholic steatohepatitis form alcoholic liver disease. Am J Gastroenterol, 1999;94:1018- 1022.
Referências bibliográficas
92. Pinto HC, Baptista A, Camilo ME et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci, 1996;41:172-179.
93. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126(2):137–145.
94. Clinical Practice Committee AGA. AGA medical position statement: evaluation of liver chemistry tests. Gastroenterology 2003;123:1364–1366
95. Choudhury: Semin Liver Dis, Volume 24(4).November 2004.349–362
96. National Institutes of Health. Symposium on Non-alcoholic Steatohepatitis. Bethesda, Maryland, 1998.
97. Oliveira CPMS, Gayotto LCC, Tatai C et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline- deficient diet. J Cell Mol Med 2002; 6: 399-406.
98. Oliveira, C PMS; Rascovski, A; Bastos, M S; Matsuda, M; Laudanna, A A; Halpern, A Oxidative Stress In Nonalcoholic Fatty Liver Disease (Nafld) In Morbid Obesity. International Journal of Obesity 20003; 27 Supplement 1:S140.
99. Oliveira, CPMS, Faintuch, J, Rascovski, A, Furuya Jr, CK, Bastos, MS , Matsuda, M, Nina, BID, Yahnos,i K, Abdala, DSP, Vezozzo, DCP, Alves, VAF, Zilberstein, B, Garrido Jr, AB, Halpern, A, Carrilho, FJ , Gama-Rodrigues, JJ.
Referências bibliográficas
Lipid Peroxidation in Bariatric Candidates with Nonalcoholic Fatty Liver Disease (NAFLD) – Preliminary findings. Obes Surg. 2005 Apr;15(4):502-5.
100. Cotrim, HP - Esteato-Hepatite Não Alcoólica. Cotrim, HP - Esteato- Hepatite Não Alcoólica. Obesidade Diabetes e Complicações. 2002. 2 (2): 85- 93.
101. Cotrim, H.P., Freitas LA et al. - Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver, 1999. 19(4): p. 299-304.
102. Cotrim, H.P., et al. - Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol, 2000. 95(10): p. 3018-9.
103. Lee WJ. Huang MT. Wang W. Lin CM. Chen TC. Lai IR. Effects of obesity surgery on the metabolic syndrome. [Clinical Trial. Controlled Clinical Trial. Journal Article] Archives of Surgery. 2004; 139(10):1088-92.
104. Dixon JB, O’Brien PE: Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25:358–363.
105. Buchwald H. Avidor Y. Braunwald E. Jensen MD. Pories W. Fahrbach K. Schoelles K. Bariatric surgery: a systematic review and meta-analysis . JAMA. 2004; 292(14):1724-37.
Referências bibliográficas
106. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715–722.
107. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200.
108. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care. 2001;24:1936–1940.
109. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
110. Blackburn GL. Mun EC. Effects of weight loss surgeries on liver disease. Seminars in Liver Disease 2004; 24(4):371-9.
111. Papadia FS. Marinari GM. Camerini G. Murelli F. Carlini F. Stabilini C. Scopinaro N. Liver damage in severely obese patients: a clinical-biochemical- morphologic study on 1,000 liver biopsies. Obesity Surgery. 2004; 14(7):952-8.
Referências bibliográficas
112. Shalhub S. Parsee A. Gallagher SF. Haines KL. Willkomm C. Brantley SG. Pinkas H. Saff-Koche L. Murr MM. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obesity Surgery. 2004; 14(1):54-9.
113. Ong JP. Elariny H. Collantes R. Younoszai A. Chandhoke V. Reines HD. Goodman Z. Younossi ZM. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obesity Surgery. 2005; 15(3):310- 5.
114. Crespo J. Fernandez-Gil P. Hernandez-Guerra M. Cayon A. Mayorga M. Dominguez-Diez A. Fernandez-Escalante JC. Pons-Romero F. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non- alcoholic steatohepatitis?. Obesity Surgery. 2001; 11(3):254-7.
115. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373–9.
116. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929–34.
117. Gillum RF, Mussolino ME, Madans JH. Body fat distribution and hypertension incidence in women and men. The NHANES I epidemiologic follow-up study. Intern J Obesity Relat Disord 1998;22:127–34.
Referências bibliográficas
118. Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353–8.
119. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of metabolic syndrome. Diabetes 2001;50:1844–50.
120. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367–72.
121. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.
122. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71–9.
123. Sheth SG, Gordon FD, Chopra S. Non-alcoholic steato-hepatitis. Ann Intern Med 1997;126:137-145
124. Sanyal AJ. Non-alcoholic steatohepatitis. Clin Perspect Gastroenterol 2000;(May/June):129-139
125. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75:733-739 .
Referências bibliográficas
126. VanNess MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-478
127. Babb R. Letter to the Editor. N Engl J Med 2002;347:768–9.
128. Joy D, Scott BB. To perform or not to perform liver biopsy: an alternative view. Gut 2003;52:610.
129. Friis-Liby, I.; Aldenborg, F.; Jerlstad, P.; Rundstrom, K.; Bjornsson, E. High Prevalence of Metabolic Complications in Patients with Non-Alcoholic Fatty Liver Disease. Scandinavian Journal of Gastroenterology. 2004; 39(9):864-869.
130. Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 2003;124:1821–9.
131. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994. Accessed January 11, 2004.
132. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millenium. Am J Gastroenterol 2002;97(11):2714-24.
133. Koruk M. Taysi S. Savas MC. Yilmaz The. Akcay F. Karakok M. Serum Levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turkish Journal of Gastroenterology. 2003; 14(1):12-7.
Referências bibliográficas
134. Giannini, Edoardo G.; Testa, Roberto; Savarino, Vincenzo Liver enzyme alteration: a guide for clinicians. CMAJ Canadian Medical Association Journal. February 1, 2005; 172(3):367-379.
135. Williams MJ, Poulton R, Williams S. Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis. 2002 Nov;165(1):179-84.
136. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana- Abella R, Cabrero D, Fernandez-Castaner M, Soler J.Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998 Jan;21(1):62-8.
137. Halle M, Konig D, Berg A, Keul J, Baumstark MW.Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis. 1997 Feb 10;128(2):235- 40.
138. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults.. Diabetes Care. 2004 Oct;27(10):2422-8.
139. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ. Serum ferritin levels in poorly- and well-controlled diabetes mellitus. Endocr Res. 2003 Aug;29(3):299- 306.
Referências bibliográficas
140. Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002 Oct 4;91(7):570-6.
141. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.. Gastroenterology. 2003 Jan;124(1):71-9.
142. Miyake Y, Eguchi H, Shinchi K, Oda T, Sasazuki S, Kono S. Glucose intolerance and serum aminotransferase activities in Japanese men. J Hepatol. 2003 Jan;38(1):18-23.
143. Bruckert E, Giral P, Ratziu V, Poynard T, Chapman MJ, Opolon P, Turpin G. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metabolism. 2002 Aug;51(8):1071- 6.
144. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med. 2000 Sep;248(3):230-8.
145. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Haring H, Stumvoll M. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005 Apr;37(4):246-51
Referências bibliográficas
146. Laaksonen DE, Kainulainen S, Rissanen A, Niskanen L Relationships between changes in abdominal fat distribution and insulin sensitivity during a very low calorie diet in abdominally obese men and women. Nutr Metab Cardiovasc Dis. 2003 Dec;13(6):349-56.
147. Sindelka G, Skrha J, Prazny M, Hilgertova J [The effect of body weight on